Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
06 mai 2021 07h03 HE
|
Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
Trevena Reports First Quarter 2021 Results
06 mai 2021 07h00 HE
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
Trevena to Release First Quarter 2021 Financial Results on May 6, 2021
05 mai 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
29 avr. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients
21 avr. 2021 07h00 HE
|
Trevena Inc.
-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data...
Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting
15 avr. 2021 07h30 HE
|
Trevena Inc.
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) --...
Trevena, Inc. Appoints Marvin H. Johnson, Jr. to Board of Directors
18 mars 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
09 mars 2021 07h00 HE
|
Trevena Inc.
-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...
Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
05 mars 2021 07h00 HE
|
Trevena Inc.
-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET -- CHESTERBROOK, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused...
Trevena, Inc. to Participate in March Virtual Investor Conferences
01 mars 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...